Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Journal of Urology

• Publication date

  1989-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0022-5347(17)41176-1PMID 2468796
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.

  1989cited by this paper
• Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen.

  1989cited by this paper
• Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.

  1989cited by this paper
• Status of radiation treatment of prostate cancer at Stanford University.

  1989cited by this paper
• Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients.

  1989cited by this paper
• Ultrasound guided transrectal core biopsies of the palpably abnormal prostate.

  1989cited by this paper
• Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

  1988cited by this paper
• Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate

  1987cited by this paper
• Selecting initial therapy for prostate cancer. Radiation therapy perspective

  1987cited by this paper
• The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer.

  1986cited by this paper
• Interstitial radiation: short-term palliation or curative therapy?

  1985cited by this paper
• Carcinoma of the prostate: Results of post‐irradiation biopsy

  1984cited by this paper
• Radiotherapy for prostatic carcinoma: post-irradiation prostatic biopsy and recurrence patterns with long-term followup.

  1982cited by this paper
• Immunohistochemical evaluation of prostatic carcinoma before and after radiotherapy.

  1980cited by this paper
• External beam radiotherapy for adenocarcinoma of the prostate: a clinical followup.

  1980cited by this paper

• Early PSA kinetics for low- and intermediate-risk prostate cancer treated with definitive radiation therapy.

  2021cites this paper
• Clinical and Novel Biomarkers in the Management of Prostate Cancer

  2018cites this paper
• Assessment of Prostate Cancer Radiation Therapy Using PSA Level

  2017cites this paper
• Prospective investigation of change in the prostate-specific antigens after various urologic procedures

  2015cites this paper
• Antibiotics may not decrease prostate-specific antigen levels or prevent unnecessary prostate biopsy in patients with moderately increased prostate-specific antigen levels: A meta-analysis.

  2015cites this paper
• Prospective investigation of change in the prostate-specific antigens after various urologic procedures

  2015cites this paper
• Prospective investigation of change in the prostate-specific antigens after various urologic procedures

  2015cites this paper
• Prospective investigation of change in the prostate-specific antigens after various urologic procedures

  2015cites this paper
• TREATMENT RESPONSE ON THE LEVEL OF PROSTATE SPECIFIC ANTIGEN (PSA)

  2015cites this paper
• Permanent Prostate Brachytherapy Dosimetry: Critical Assessments and Advancements

  2014cites this paper
• CYP17A1 polymorphisms and clinical outcome of patients with metastatic castration-resistant prostate cancer treated with abiraterone

  2014cites this paper
• Is the PSA Era Over

  2013cites this paper
• The Effect of Antibiotherapy on Prostate-Specific Antigen Levels and Prostate Biopsy Results in Patients with Levels 2.5 to 10 ng/mL

  2013cites this paper
• PSA-Screening und Tastuntersuchung bereits ab 40 empfohlen

  2012cites this paper
• Early Detection, Diagnosis, and Staging of Prostate Cancer

  2012cites this paper
• High-risk prostate cancer: from definition to contemporary management.

  2012cites this paper
• [Early diagnosis of prostate cancer].

  2012cites this paper
• Beyond PSA: Promising New Markers for Prostate Cancer

  2012cites this paper
• Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times

  2011cites this paper
• Low-dose rate brachytherapy for men with localized prostate cancer.

  2011cites this paper
• Grouping Priors and the Bayesian Elastic Net Luke

  2010cites this paper
• Grouping Priors and the Bayesian Elastic Net

  2010cites this paper
• Screening by the prostate-specific antigen test: what do the patients know?

  2009cites this paper
• Conditional Likelihood for Risk Estimation in Genome Scans and Coefficient Shrinkage

  2009cites this paper
• Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs

  2009cites this paper
• PSA – eesnäärmevähi diagnostika, skriiningu ja jälgimise marker

  2009influential citation
• Prognostic Markers in Prostate Cancer: Clinical Value

  2008cites this paper
• ACR appropriateness criteria.

  2008cites this paper
• Relationship between histologic grading and serum prostate specific antigen in prostatic carcinoma

  2007cites this paper
• Increasing role of prostate specific antigen (PSA) in the clinical staging of prostate cancer patients

  2007cites this paper
• Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate

  2006cites this paper
• Annotation of androgen dependence to human prostate cancer-associated genes by microarray analysis of mouse prostate.

  2006cites this paper
• INDUCTION OF T-CELL RESPONSES AGAINST PSA BY

  2005cites this paper
• Induction of t-cell responses against PSA by plasmid DNA immunization

  2005cites this paper
• Periodic health examination, 1991 update: 3. Secondary prevention of prostate cancer

  2005cites this paper
• Iodine-125 brachytherapy for prostate cancer: first published Australian experience.

  2004cites this paper
• Loss of cervical spinal curvature during radiotherapy for head-and-neck cancers: the neck moves, too.

  2004cites this paper
• E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma

  2004cites this paper
• General anesthesia does not affect the serum complexed and free prostate specific antigen levels.

  2004cites this paper
• An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and prostate-specific antigen density

  2004cites this paper
• In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia

  2003cites this paper
• Post-Biopsy Rise in Serum PSA : A Potential Tool for the Dynamic Evaluation of Prostate Cancer/Prostatic Intraepithelial Neoplasia (PIN)

  2003cites this paper
• REVIEW Clinical usefulness of tumour markers

  2003cites this paper
• Detektion von Prostata-spezifisches Antigen (PSA-)mRNA-exprimierenden Zellen im peripheren Blut mittels Reverse-transcription-nested-Polymerasekettenreaktion (RT-nested-PCR)

  2002cites this paper
• Molecular Genetics of Prostate Cancer

  2002cites this paper
• Efectividad y seguridad de la radioterapia externa y de la cirugía radical en el cáncer de próstata localizado

  2001cites this paper
• Non‐specific eosinophilic granulomatous prostatitis responded favorably to an antimicrobial agent and a hydrocortisone

  2001cites this paper
• Antitumor Efficacy without Increasing Toxicity Combination with Radiotherapy Produces Synergistic CV 706 , a Prostate Cancer-specific Adenovirus Variant , in Updated Version

  2001cites this paper
• CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity.

  2001cites this paper
• The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States.

  2001cites this paper
• Ki–67 Index in Metastatic Prostate Cancer

  2001cites this paper
• Prostate cancer and life insurance.

  2000cites this paper
• Prostate cancer and life insurance.

  2000cites this paper
• Management of locally advanced prostate cancer

  2000cites this paper
• Salvage Radical Prostatectomy after Radiation Therapy and Brachytherapy

  2000cites this paper
• Ad5CMVp53 gene therapy for locally advanced prostate cancer – where do we stand?

  2000cites this paper
• [Bone scan and prostate cancer].

  2000cites this paper
• High- and Low-Risk Prostate Cancer Treated with 3D CT-Guided Brachytherapy: 1-to 5-Year Follow-up

  2000cites this paper
• Salvage brachytherapy for localized prostate cancer after radiotherapy failure.

  1999cites this paper
• Prostate-specific antigen.

  1999cites this paper
• Definitive Strahlentherapie des Prostatakarzinoms

  1999cites this paper
• Die Rolle des PSA in der Diagnostik und des Prostatakarzinoms

  1999cites this paper
• ACR appropriateness criteria. Expert Panel on Radiation Oncology. American College of Radiology.

  1999cites this paper
• Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL.

  1999cites this paper
• The effect of colonoscopy on serum prostate specific antigen levels

  1999cites this paper
• Prostate specific antigen levels in the follow up of localised prostate cancer: how does radiotherapy compare to radical prostatectomy?

  1999cites this paper
• Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy.

  1999cites this paper
• Malignancy of the Prostate Gland

  1998cites this paper
• The histology of radiation therapy effect on prostate adenocarcinoma as assessed by needle biopsy after brachytherapy boost. Correlation with biochemical failure.

  1998cites this paper
• [Probability of seminal vesicle involvement in localized prostatic carcinoma. Significance in conformal radiotherapy].

  1998cites this paper
• Sonography of Carcinoma of the Prostate

  1998cites this paper
• Salvage radical cystoprostatectomy and orthotopic urinary diversion following radiation failure.

  1998cites this paper
• BROADSHEET NUMBER 42: PROSTATE SPECIFIC ANTIGEN UPDATE

  1998cites this paper
• Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.

  1998cites this paper
• Specificity and accuracy of TRUS-measured PSA-density and transition zone-PSA in the diagnosis of prostate cancer.

  1998cites this paper
• Wahrscheinlichkeit des Samenblasenbefalls beim lokal begrenzten Prostatakarzinom

  1998cites this paper
• Kombinierte Brachytherapie und antiandrogene Therapie beim Prostatakarzinom

  1998cites this paper
• Neoadjuvant hormonal therapy and radical prostatectomy in the treatment of clinical stage T3 cancer of the prostate.

  1998cites this paper
• Prognostic value of prostate specific antigen before, during and after radiotherapy.

  1998cites this paper
• Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol)

  1998cites this paper
• PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it?

  1998cites this paper
• Influence of noncancerous prostatic tissue volume on prostate-specific antigen.

  1998cites this paper
• Value of sextant biopsies in the assessment of local cure following external beam radiotherapy of prostatic adenocarcinoma.

  1998cites this paper
• Analysis of the local control in lymph-node staged localized prostate cancer treated by external beam radiotherapy, assessed by digital rectal examination, serum prostate-specific antigen and biopsy.

  1997cites this paper
• Using prostate-specific antigen to eliminate the staging radionuclide bone scan.

  1997cites this paper
• THE EFFECTS OF PROSTATIC SPECIFIC ANTIGEN LEVELS MANIPULATION ON PROSTATE

  1997cites this paper
• Editorial: Prostate Specific Antigen

  1997cites this paper
• Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer.

  1997cites this paper
• Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.

  1997cites this paper
• Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma

  1997cites this paper
• Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy.

  1997cites this paper
• Biochemical disease-free survival following 125I prostate implantation.

  1997cites this paper
• Localized Carcinoma of the Prostate: Patterns of Failure with External Beam Radiation Therapy

  1996cites this paper
• External beam radiation therapy does not offer long-term control of prostate cancer.

  1996cites this paper
• Histological characteristics of radical prostatectomy specimens in men with a serum prostate specific antigen of 4 ng./ml or less.

  1996cites this paper
• La ponction biopsie de prostate

  1996cites this paper
• Is "off-protocol" chemotherapy for androgen-independent carcinoma of prostate warranted?

  1996cites this paper
• Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancer.

  1996cites this paper
• Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients.

  1996cites this paper
• Treatment options for localized recurrence of prostate cancer following radiation therapy.

  1996cites this paper